171 related articles for article (PubMed ID: 16918475)
1. Structure and mechanism of arylamine N-acetyltransferases.
Westwood IM; Kawamura A; Fullam E; Russell AJ; Davies SG; Sim E
Curr Top Med Chem; 2006; 6(15):1641-54. PubMed ID: 16918475
[TBL] [Abstract][Full Text] [Related]
2. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function.
Sim E; Pinter K; Mushtaq A; Upton A; Sandy J; Bhakta S; Noble M
Biochem Soc Trans; 2003 Jun; 31(Pt 3):615-9. PubMed ID: 12773167
[TBL] [Abstract][Full Text] [Related]
3. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases.
Brooke EW; Davies SG; Mulvaney AW; Pompeo F; Sim E; Vickers RJ
Bioorg Med Chem; 2003 Apr; 11(7):1227-34. PubMed ID: 12628650
[TBL] [Abstract][Full Text] [Related]
4. The pharmacogenetics of NAT: structural aspects.
Pompeo F; Brooke E; Kawamura A; Mushtaq A; Sim E
Pharmacogenomics; 2002 Jan; 3(1):19-30. PubMed ID: 11966400
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines.
Sandy J; Mushtaq A; Holton SJ; Schartau P; Noble ME; Sim E
Biochem J; 2005 Aug; 390(Pt 1):115-23. PubMed ID: 15869465
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of arylamine N-acetyltransferases: insights into the mechanisms of action and substrate selectivity.
Kubiak X; Dairou J; Dupret JM; Rodrigues-Lima F
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):349-62. PubMed ID: 23289949
[TBL] [Abstract][Full Text] [Related]
7. Arylamine N-acetyltransferases: from structure to function.
Sim E; Walters K; Boukouvala S
Drug Metab Rev; 2008; 40(3):479-510. PubMed ID: 18642144
[TBL] [Abstract][Full Text] [Related]
8. Structural and biochemical characterization of an active arylamine N-acetyltransferase possessing a non-canonical Cys-His-Glu catalytic triad.
Kubiak X; Li de la Sierra-Gallay I; Chaffotte AF; Pluvinage B; Weber P; Haouz A; Dupret JM; Rodrigues-Lima F
J Biol Chem; 2013 Aug; 288(31):22493-505. PubMed ID: 23770703
[TBL] [Abstract][Full Text] [Related]
9. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
10. Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase.
Fullam E; Westwood IM; Anderton MC; Lowe ED; Sim E; Noble ME
J Mol Biol; 2008 Jan; 375(1):178-91. PubMed ID: 18005984
[TBL] [Abstract][Full Text] [Related]
11. Arylamine N-acetyltransferases: a structural perspective.
Zhou X; Ma Z; Dong D; Wu B
Br J Pharmacol; 2013 Jun; 169(4):748-60. PubMed ID: 23517104
[TBL] [Abstract][Full Text] [Related]
12. Eubacterial arylamine N-acetyltransferases - identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues.
Payton M; Mushtaq A; Yu TW; Wu LJ; Sinclair J; Sim E
Microbiology (Reading); 2001 May; 147(Pt 5):1137-1147. PubMed ID: 11320117
[TBL] [Abstract][Full Text] [Related]
13. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity.
Mushtaq A; Payton M; Sim E
J Biol Chem; 2002 Apr; 277(14):12175-81. PubMed ID: 11799105
[TBL] [Abstract][Full Text] [Related]
14. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
Sim E; Abuhammad A; Ryan A
Br J Pharmacol; 2014 Jun; 171(11):2705-25. PubMed ID: 24467436
[TBL] [Abstract][Full Text] [Related]
15. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazid.
Sandy J; Mushtaq A; Kawamura A; Sinclair J; Sim E; Noble M
J Mol Biol; 2002 May; 318(4):1071-83. PubMed ID: 12054803
[TBL] [Abstract][Full Text] [Related]
16. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
Sim E; Fakis G; Laurieri N; Boukouvala S
Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
[TBL] [Abstract][Full Text] [Related]
17. Kinetic characterisation of arylamine N-acetyltransferase from Pseudomonas aeruginosa.
Westwood IM; Sim E
BMC Biochem; 2007 Mar; 8():3. PubMed ID: 17374145
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional characterization of an arylamine N-acetyltransferase from the pathogen Mycobacterium abscessus: differences from other mycobacterial isoforms and implications for selective inhibition.
Cocaign A; Kubiak X; Xu X; Garnier G; Li de la Sierra-Gallay I; Chi-Bui L; Dairou J; Busi F; Abuhammad A; Haouz A; Dupret JM; Herrmann JL; Rodrigues-Lima F
Acta Crystallogr D Biol Crystallogr; 2014 Nov; 70(Pt 11):3066-79. PubMed ID: 25372695
[TBL] [Abstract][Full Text] [Related]
19. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies.
Wang H; Vath GM; Gleason KJ; Hanna PE; Wagner CR
Biochemistry; 2004 Jun; 43(25):8234-46. PubMed ID: 15209520
[TBL] [Abstract][Full Text] [Related]
20. Structure of Mesorhizobium loti arylamine N-acetyltransferase 1.
Holton SJ; Dairou J; Sandy J; Rodrigues-Lima F; Dupret JM; Noble ME; Sim E
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2005 Jan; 61(Pt 1):14-6. PubMed ID: 16508079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
